Journal article
Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Abstract
OBJECTIVE: To review the evidence concerning alendronate (Fosamax) therapy for postmenopausal osteoporosis.
QUALITY OF EVIDENCE: The efficacy of alendronate for postmenopausal women with osteoporosis was primarily demonstrated by two primary phase III clinical trials, three other 2-year trials, and one 3-year trial. All six trials were randomized double-blind placebo-controlled trials; 3854 postmenopausal women were studied. The Fracture …
Authors
Adachi JD
Journal
Canadian Family Physician, Vol. 44, , pp. 327–332
Publication Date
2 1998
ISSN
0008-350X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAlendronateBone DensityBone and BonesCalcification, PhysiologicClinical Trials, Phase III as TopicDouble-Blind MethodDrug Administration ScheduleFemaleFemurFemur NeckFractures, BoneHip FracturesHumansLumbar VertebraeMiddle AgedOsteoporosis, PostmenopausalPlacebosRandomized Controlled Trials as TopicRisk FactorsSafetySpinal FracturesTreatment Outcome